

ONE

CP/1655
#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicants: Peter M. Glazer

AUG 09 2002

Serial No.: 09/978,333

Art Unit: 1655

TECH CENTER 1600/2900

Filed: October 15, 2001

Examiner: Not Yet Assigned

For: *TRIPLE-HELIX FORMING OLIGONUCLEOTIDES FOR TARGETED
MUTAGENESIS*

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits an Information Disclosure Statement, including seven (7) pages of Form PTO-1449 and a copy of each document cited therein.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
5,962,426	10-05-1999	Glazer	514/44
5,422,251	06-06-1995	Fresco	435/91.1

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 95/01364	01/12/1995	Yale University	PCT

Publications

BAUMANN, et al., "Role of the human RAD51 protein in homologous recombination and double-stranded-break repair," *Trends Biochem Sci* 23(7):247-251 (1998).

BEAL, et al., "Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation," *Science* 251:1360-1363 (1991).

BEAL, et al., "The influence of single base triplet changes on the stability of Pur·Pur·Pyr triple helix determined by affinity cleaving," *Nuc. Acids Res.* 20(11):2773-2776 (1992).

BLUME, et al., "Triple helix formation by purine-rich oligonucleotides targeted to the human dihydrofolate reductase promoter," *Nucleic Acids Res.* 20:1777-1784 (1992).

BRENNEMAN, *et al.*, "Stimulation of intrachromosomal homologous recombination in human cells by electroporation with site-specific endonucleases," *Proc. Natl. Acad. Sci. USA* 93(8): 3608-12 (1996).

CAMPBELL, *et al.*, "Homologous recombination involving small single-stranded oligonucleotides in human cells," *New Biol.* 1(2):223-7 (1989).

CAPECCHI, "Altering the genome by homologous recombination," *Science* 244(4910): 1288-1292 (1989).

CHAN, et al., "Targeted correction of an episomal gene in mammalian cells by a short DNA fragment tethered to a triplex-forming oligonucleotide," *J. Biol. Chem.* 274(17): 11541-11548 (1999).

COONEY, *et al.*, "Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro," *Science* 241: 456-459 (1988).

DURLAND, *et al.*, "Binding of triple helix forming oligonucleotides to sites in gene promoters," *Biochemistry* 30:9246-9255 (1991).

DUVAL-VALENTIN, *et al.*, "Specific inhibition of transcription by triple helix-forming oligonucleotides," *Proc. Natl. Acad. Sci. USA* 89:504-508 (1992).

FARUQI, et al., "Triple-helix formation induces recombination in mammalian cells via a nucleotide excision repair-dependent pathway," *Mol Cell Biol* 20(3): 990-1000 (2000).

FELSENFELD, et al., "Formation of a three-stranded polynucleotide molecule," *J. Am. Chem. Soc.* 79:2023-2024 (1957).

FRANCOIS, et al., "Sequence-specific recognition and cleavage of duplex DNA via triple-helix formation by oligonucleotides covalently linked to a phenanthroline-copper chelate," *Proc. Natl. Acad. Sci. USA* 86:9702-9706 (1989).

GLAZER, et al., "DNA mismatch repair detected in human cell extracts," *Mol. Cell. Biol.* 7:218-224 (1987).

GONCZ, et al., "Site-directed alteration of genomic DNA by small-fragment homologous replacement," *Methods Mol. Biol.* 133:85-89 (2000).

GRIGORIEV, et al., "A triple helix-forming oligonucleotide-intercalator conjugate acts as a transcriptional repressor via inhibition of NF kappa B binding to interleukin-2 receptor alpha-regulatory sequence," *J. of Biological Chem.* 267:3389-3395 (1992).

HANSON, et al., "Analysis of biological selections for high-efficiency gene targeting," *Mol. Cell. Biol.* 15(1):45-51 (1995).

HAVRE, et al., "Targeted mutagenesis of simian virus 40 DNA mediated by a triple helix-forming oligonucleotide," *J. Virology* 67:7324-7331 (1993).

HELENE, "Sequence-selective recognition and cleavage of double-helical DNA," *Curr. Opinion Biotechnology* 4:29-36 (1993).

ITO, et al., "Sequence-specific DNA purification by triplex affinity capture," *Proc. Natl. Acad. Sci. USA* 89:495-498 (1992).

JAKUBCZAK, et al., "Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage lambda transgene target," *Proc. Natl. Acad. Sci. USA* 93:9073-9078 (1996).

JONES, et al., "Preferential binding of the xeroderma pigmentosum group A complementing protein to damaged DNA," *Biochemistry* 32:12096-12104 (1993).

LETAI, et al., "Specificity in formation of triple-stranded nucleic acid helical complexes: studies with agarose-linked polyribonucleotide affinity columns," *Biochemistry* 27:9108-9112 (1988).

LIN, *et al.*, "Extrachromosomal recombination in mammalian cells as studied with single- and double-stranded DNA substrates," *Mol. Cell Biol* 7(1):129-140 (1987).

LIN, *et al.*, "Use of EDTA derivatization to characterize interactions between oligodeoxyribonucleoside methylphosphonates and nucleic acids," *Biochemistry* 28:1054-1061 (1989).

LUO, *et al.*, "High-frequency intrachromosomal gene conversion induced by triplex-forming oligonucleotides microinjected into mouse cells," *Proc. Natl. Acad. Sci. USA* 97(16): 9003-9008 (2000).

MAHER, *et al.*, "Analysis of promoter-specific repression by triple-helical DNA complexes in a eukaryotic cell-free transcription system," *Biochemistry* 31:70-81 (1992).

MAHER, *et al.*, "Inhibition of DNA binding proteins by oligonucleotide-directed triple helix formation," *Science* 245:725-730 (1989).

MERGNY, *et al.*, "Sequence specificity in triple-helix formation: experimental and theoretical studies of the effect of mismatches on triplex stability," *Biochemistry* 30:9791-9798 (1991).

MOSER, *et al.*, "Sequence-specific cleavage of double helical DNA by triple helix formation," *Science* 238:645-650 (1987).

MYHR, "Validation studies with Muta Mouse: a transgenic mouse model for detecting mutations in vivo," *Environ. Mol. Mutagen* 18:308-315(1991).

NARAYANAN, *et al.*, "Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2," *Proc. Natl. Acad. Sci. USA* 94:3122-3127 (1997).

ORSON, *et al.*, "Oligonucleotide inhibition of IL2R alpha mRNA transcription by promoter region collinear triplex formation in lymphocytes," *Nucleic Acids Res.* 19:3435-3441 (1991).

PARK, *et al.*, "Formation of a ternary complex by human XPA, ERCC1, and ERCC4(XPF) excision repair proteins," *Proc. Natl. Acad. Sci. USA* 91:5017-5021 (1994).

PARRIS, *et al.*, "Proximal and distal effects of sequence context on ultraviolet mutational hotspots in a shuttle vector replicated in xeroderma cells," *J Mol Biol.* 236:491-502 (1994).

PEI, *et al.*, "Site-specific cleavage of duplex DNA by a semisynthetic nuclease via triple-helix formation," *Proc. Natl. Acad. Sci. USA* 87:9858-9862 (1990).

PERROUALT, *et al.*, "Sequence-specific artificial photo-induced endonucleases based on triple helix-forming oligonucleotides," *Nature* 344:358-360 (1990).

POSTEL, *et al.*, "Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels," *Proc. Natl. Acad. Sci. USA* 88:8227-8231 (1991).

POSVIC, *et al.*, "Sequence-Specific Alkylation of Double-Helix DNA by Oligonucleotide-Directed Triple-Helix Formation," *J. Am. Chem. Soc.* 112:9428-9430 (1990).

PRASEUTH, *et al.*, "Sequence-specific binding and photocrosslinking of alpha and beta oligodeoxynucleotides to the major groove of DNA via triple-helix formation," *Proc. Natl. Acad. Sci. USA* 85:1349-1353 (1988).

REARDON, *et al.*, "Removal of psoralen monoadducts and crosslinks by human cell free extracts," *Nucleic Acids Res.* 19:4623-4629 (1991).

SAMBROOK, *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL, second edition, Cold Spring Harbor Laboratory Press, New York (1990).

SANCAR, "DNA excision repair," *Annu. Rev. Biochem.* 65:43-81 (1996).

SHIVJI, *et al.*, "Proliferating cell nuclear antigen is required for DNA excision repair," *Cell* 69: 367-374 (1992).

SIBGHAT-ULLAH, *et al.*, "Human nucleotide excision repair in vitro: repair of pyrimidine dimers, psoralen and cisplatin adducts by HeLa cell-free extract," *Nucleic Acids Res.* 17:4471-4484 (1989).

STROBEL, *et al.*, "Site-specific cleavage of human chromosome 4 mediated by triple-helix formation," *Science* 254:1639-1642 (1991).

SUNG, *et al.*, "Recombination factors of *Saccharomyces cerevisiae*," *Mutat Res* 451:257-75 (2000).

TAKASUGI, *et al.*, "Sequence-specific photo-induced cross-linking of the two strands of double-helical DNA by a psoralen covalently linked to a triple helix-forming oligonucleotide," *Proc. Natl. Acad. Sci. USA* 88:5602-5606 (1991).

THACKER, "A surfeit of RAD51-like genes?," *Trends Genet* 15(5):166-8 (1999).

VASQUEZ, *et al.*, "Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells," *Nucleic Acids Res.* 27:1176-1181 (1999).

WANG, *et al.*, "Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair," *Science* 271: 802-805 (1996).

WANG, *et al.*, "Targeted mutagenesis in mammalian cells mediated by intracellular triple helix formation," *Mol. Cell. Biol.* 15:1759-1768 (1995).


WOOD, *et al.*, "Complementation of the xeroderma pigmentosum DNA repair defect in cell-free extracts," *Cell* 53:97-106 (1988).

YOUNG, *et al.*, "Triple helix formation inhibits transcription elongation in vitro," *Proc. Natl. Acad. Sci. USA* 88:10023-10026 (1991).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: July 31, 2002


HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com

U.S.S.N.: 09/978,333
Filed: October 15, 2001
INFORMATION DISCLOSURE STATEMENT

RECEIVED

AUG 09 2002

TECH CENTER 1600/2900



Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: July 31, 2002


Brent A. Winitt

ATL1 #525653 v1

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Use as many sheets as necessary)		Application Number	09/978,333
		Filing Date	October 15, 2001
		First Named Inventor	Peter M. Glazer
		Group Art Unit	1655
		Examiner Name	
Attorney Docket Number	YU 132 (OCR 653)		



TECH CENTER 160012900

AUG 09 2002

RECEIVED

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		BAUMANN, et al., "Role of the human RAD51 protein in homologous recombination and double-stranded-break repair," <i>Trends Biochem Sci</i> 23(7):247-251 (1998).	
		BEAL, et al., "Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation," <i>Science</i> 251:1360-1363 (1991).	
		BEAL, et al., "The influence of single base triplet changes on the stability of Pur-Pur-Pyr triple helix determined by affinity cleaving," <i>Nuc. Acids Res.</i> 20(11):2773-2776 (1992).	
		BLUME, et al., "Triple helix formation by purine-rich oligonucleotides targeted to the human dihydrofolate reductase promoter," <i>Nucleic Acids Res.</i> 20:1777-1784 (1992).	
		BRENNEMAN, et al., "Stimulation of intrachromosomal homologous recombination in human cells by electroporation with site-specific endonucleases," <i>Proc. Natl. Acad. Sci. USA</i> 93(8): 3608-12 (1996).	
		CAMPBELL, et al., "Homologous recombination involving small single-stranded oligonucleotides in human cells," <i>New Biol.</i> 1(2):223-7 (1989).	
		CAPECCHI, "Altering the genome by homologous recombination," <i>Science</i> 244(4910): 1288-1292 (1989).	
		CHAN, et al., "Targeted correction of an episomal gene in mammalian cells by a short DNA fragment tethered to a triplex-forming oligonucleotide," <i>J. Biol. Chem.</i> 274(17): 11541-11548 (1999).	
		COONEY, et al., "Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro," <i>Science</i> 241: 456-459 (1988).	
		DURLAND, et al., "Binding of triple helix forming oligonucleotides to sites in gene promoters," <i>Biochemistry</i> 30:9246-9255 (1991).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/978,333
		Filing Date	October 15, 2001
		First Named Inventor	Peter M. Glazer
		Group Art Unit	1655
		Examiner Name	
		Attorney Docket Number	YU 132 (OCR 653)



OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		DUVAL-VALENTIN, <i>et al.</i> , "Specific inhibition of transcription by triple helix-forming oligonucleotides," <i>Proc. Natl. Acad. Sci. USA</i> 89:504-508 (1992).	
		FARUQI, <i>et al.</i> , "Triple-helix formation induces recombination in mammalian cells via a nucleotide excision repair-dependent pathway," <i>Mol Cell Biol</i> 20(3): 990-1000 (2000).	
		FELSENFELD, <i>et al.</i> , "Formation of a three-stranded polynucleotide molecule," <i>J. Am. Chem. Soc.</i> 79:2023-2024 (1957).	
		FRANCOIS, <i>et al.</i> , "Sequence-specific recognition and cleavage of duplex DNA via triple-helix formation by oligonucleotides covalently linked to a phenanthroline-copper chelate," <i>Proc. Natl. Acad. Sci. USA</i> 86:9702-9706 (1989).	
		GLAZER, <i>et al.</i> , "DNA mismatch repair detected in human cell extracts," <i>Mol. Cell. Biol.</i> 7:218-224 (1987).	
		GONCZ, <i>et al.</i> , "Site-directed alteration of genomic DNA by small-fragment homologous replacement," <i>Methods Mol. Biol.</i> 133:85-89 (2000).	
		GRIGORIEV, <i>et al.</i> , "A triple helix-forming oligonucleotide-intercalator conjugate acts as a transcriptional repressor via inhibition of NF kappa B binding to interleukin-2 receptor alpha-regulatory sequence," <i>J. of Biological Chem.</i> 267:3389-3395 (1992).	
		HANSON, <i>et al.</i> , "Analysis of biological selections for high-efficiency gene targeting," <i>Mol. Cell. Biol.</i> 15(1):45-51 (1995).	
		HAVRE, <i>et al.</i> , "Targeted mutagenesis of simian virus 40 DNA mediated by a triple helix-forming oligonucleotide," <i>J. Virology</i> 67:7324-7331 (1993).	
		HELENE, "Sequence-selective recognition and cleavage of double-helical DNA," <i>Curr. Opinion Biotechnology</i> 4:29-36 (1993).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

AUG 09 2002

TECH CENTER 1600/280

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/978,333
		Filing Date	October 15, 2001
		First Named Inventor	Peter M. Glazer
		Group Art Unit	1655
		Examiner Name	
Sheet 1 of 7	Attorney Docket Number	YU 132 (OCR 653)	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ITO, et al., "Sequence-specific DNA purification by triplex affinity capture," <i>Proc. Natl. Acad. Sci. USA</i> 89:495-498 (1992).	✓
		JAKUBCZAK, et al., "Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage lambda transgene target," <i>Proc. Natl. Acad. Sci. USA</i> 93:9073-9078 (1996).	✓
		JONES, et al., "Preferential binding of the xeroderma pigmentosum group A complementing protein to damaged DNA," <i>Biochemistry</i> 32:12096-12104 (1993).	✓
		LETAI, et al., "Specificity in formation of triple-stranded nucleic acid helical complexes: studies with agarose-linked polyribonucleotide affinity columns," <i>Biochemistry</i> 27:9108-9112 (1988).	✓
		LIN, et al., "Extrachromosomal recombination in mammalian cells as studied with single- and double-stranded DNA substrates," <i>Mol. Cell Biol</i> 7(1):129-140 (1987).	✓
		LIN, et al., "Use of EDTA derivatization to characterize interactions between oligodeoxyribonucleoside methylenephosphonates and nucleic acids," <i>Biochemistry</i> 28:1054-1061 (1989).	✓
		LUO, et al., "High-frequency intrachromosomal gene conversion induced by triplex-forming oligonucleotides microinjected into mouse cells," <i>Proc. Natl. Acad. Sci. USA</i> 97(16): 9003-9008 (2000).	✓
		MAHER, et al., "Analysis of promoter-specific repression by triple-helical DNA complexes in a eukaryotic cell transcription system," <i>Biochemistry</i> 31:70-81 (1992).	✓
		MAHER, et al., "Inhibition of DNA binding proteins by oligonucleotide-directed triple helix formation," <i>Science</i> 246:725-728 (1989).	✓
		MERGNY, et al., "Sequence specificity in triple-helix formation: experimental and theoretical studies of the effect of mismatches on triplex stability," <i>Biochemistry</i> 30:9791-9798 (1991).	✓

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary)

Complete if Known

Application Number	09/978,333
Filing Date	October 15, 2001
First Named Inventor	Peter M. Glazer
Group Art Unit	1655
Examiner Name	
Attorney Docket Number	YU 132 (OCR 653)

Sheet 1 of 7

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		MOSER, et al., "Sequence-specific cleavage of double helical DNA by triple helix formation," <i>Science</i> 238:645-650 (1987).	✓
		MYHR, "Validation studies with Muta Mouse: a transgenic mouse model for detecting mutations in vivo," <i>Environ. Mol. Mutagen</i> 18:308-315(1991).	✓
		NARAYANAN, et al., "Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2," <i>Proc. Natl. Acad. Sci. USA</i> 94:3122-3127 (1997).	✓
		ORSON, et al., "Oligonucleotide inhibition of IL2R alpha mRNA transcription by promoter region collinear triplex formation in lymphocytes," <i>Nucleic Acids Res.</i> 19:3435-3441 (1991).	✓
✓		PARK, et al., "Formation of a ternary complex by human XPA, ERCC1, and ERCC4(XPF) excision repair proteins," <i>Proc. Natl. Acad. Sci. USA</i> 91:5017-5021 (1994).	✓
✓		PARRIS, et al., "Proximal and distal effects of sequence context on ultraviolet mutational hotspots in a shuttle vector replicated in xeroderma cells," <i>J Mol Biol.</i> 236:491-502 (1994).	✓
		PEI, et al., "Site-specific cleavage of duplex DNA by a semisynthetic nuclease via triple-helix formation," <i>Proc. Natl. Acad. Sci. USA</i> 87:9858-9862 (1990).	✓
		PERROUALT, et al., "Sequence-specific artificial photo-induced endonucleases based on triple helix-forming oligonucleotides," <i>Nature</i> 344:358-360 (1990).	✓
		POSTEL, et al., "Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels," <i>Proc. Natl. Acad. Sci. USA</i> 88:8227-8231 (1991).	✓
		POSVIC, et al., "Sequence-Specific Alkylation of Double-Helix DNA by Oligonucleotide-Directed Triple-Helix Formation," <i>J. Am. Chem Soc.</i> 112:9428-9430 (1990).	✓

Examiner's
Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 09/978,333
Filing Date October 15, 2001
First Named Inventor Peter M. Glazer
Group Art Unit 1655
Examiner Name
Attorney Docket Number YU 132 (OCR 653)

RECEIVED
AUG 0 9 2002
TECH CENTER 1600/2800



Sheet 1 of 7

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		PRASEUTH, <i>et al.</i> , "Sequence-specific binding and photocrosslinking of alpha and beta oligodeoxynucleotides to the major groove of DNA via triple-helix formation," <i>Proc. Natl. Acad. Sci. USA</i> 85:1349-1353 (1988).	
		REARDON, <i>et al.</i> , "Removal of psoralen monoadducts and crosslinks by human cell free extracts," <i>Nucleic Acids Res.</i> 19:4623-4629 (1991).	
		SAMBROOK, <i>et al.</i> , MOLECULAR CLONING: A LABORATORY MANUAL, second edition, Cold Spring Harbor Laboratory Press, New York (1990).	
		SANCAR, "DNA excision repair," <i>Annu. Rev. Biochem.</i> 65:43-81 (1996).	
		SHIVJI, <i>et al.</i> , "Proliferating cell nuclear antigen is required for DNA excision repair," <i>Cell</i> 69: 367-374 (1992).	
		SIBGHAT-ULLAH, <i>et al.</i> , "Human nucleotide excision repair in vitro: repair of pyrimidine dimers, psoralen and cisplatin adducts by HeLa cell-free extract," <i>Nucleic Acids Res.</i> 17:4471-4484 (1989).	
		STROBEL, <i>et al.</i> , "Site-specific cleavage of human chromosome 4 mediated by triple-helix formation," <i>Science</i> 254:1639-1642 (1991).	
		SUNG, <i>et al.</i> , "Recombination factors of <i>Saccharomyces cerevisiae</i> ," <i>Mutat Res</i> 451:257-75 (2000).	
		TAKASUGI, <i>et al.</i> , "Sequence-specific photo-induced cross-linking of the two strands of double-helical DNA by a psoralen covalently linked to a triple helix-forming oligonucleotide," <i>Proc. Natl. Acad. Sci. USA</i> 88:5602-5606 (1991).	
		THACKER, "A surfeit of RAD51-like genes?," <i>Trends Genet</i> 15(5):166-8 (1999).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary)

Complete if Known

Application Number	09/978,333
Filing Date	October 15, 2001
First Named Inventor	Peter M. Glazer
Group Art Unit	1655
Examiner Name	
Attorney Docket Number	YU 132 (OCR 653)

Sheet 1 of 7

RECEIVED
AUG 0 9 2002
TECH CENTER 1600/2800

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		VASQUEZ, <i>et al.</i> , "Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells," <i>Nucleic Acids Res.</i> 27:1176-1181 (1999).	✓
		WANG, <i>et al.</i> , "Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair," <i>Science</i> 271: 802-805 (1996).	✓
		WANG, <i>et al.</i> , "Targeted mutagenesis in mammalian cells mediated by intracellular triple helix formation," <i>Mol. Cell. Biol.</i> 15:1759-1768 (1995).	✓
		WOOD, <i>et al.</i> , "Complementation of the xeroderma pigmentosum DNA repair defect in cell-free extracts," <i>Cell</i> 53:97-106 (1988).	✓
		YOUNG, <i>et al.</i> , "Triple helix formation inhibits transcription elongation in vitro," <i>Proc. Natl. Acad. Sci. USA</i> 88:10023-10026 (1991).	✓

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+